世界のバイオシミラー(バイオ後続品)市場動向:エリトロポエチン、ヒト成長ホルモン、果粒球コロニー刺激因子、モノクローナル抗体など

◆英語タイトル:Global Biosimilar Market Outlook 2020
◆商品コード:RNCOS5042101
◆発行会社(調査会社):RNCOS
◆発行日:2015年4月
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,500 ⇒換算¥168,000見積依頼/購入/質問フォーム
Multi-User(全社内共有可)USD2,200 ⇒換算¥246,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz’s Zarxio, a G-CSF. The move is being hailed by biosimilar manufacturers and is expected to fuel numerous submissions in the coming days, making US a significant region for biosimilar activity. At the same time, as shrinking budgets are rooting for reduced healthcare expenditures and majority of blockbuster drugs are about to lose exclusivity, the biosimilar industry stands as the sole gainer.

A new research study conducted by RNCOS, “Global Biosimilar Market Outlook 2020”, reveals that the market, which was worth US$ 1.89 Billion in 2014, is expected to reach US$ 25.53 Billion by 2020, growing at an impressive CAGR of 54.4%. The report has been divided into numerous sections that deal with the various aspects of the market.

In the report, industry has been segmented based on the different classes of biosimilars available in the market, such as, mAbs, Insulin, Erythropoeitin (EPOs), Human Growth Hormone (HGH) and Interferons. The second segmentation divides the industry on the basis of major geographies which includes Europe, Asia-Pacific, and Others (including the US, Latin America and Middle-Eastern countries).

The market is subjected to various drivers as well as challenges, which have, and will continue to mould it. It is expected that the constricting healthcare budgets, approaching patent cliff and low cost of biosimilars will serve as the major drivers for the market. However, issues associated with manufacturing capabilities, litigation risks, high cost of development and substitutability may act as bottlenecks for the industry. The report talks about the various applications and technological trends that have emerged in the past few years.

This report also highlights key players and their current market share in the biosimilar domain. For every player, a brief business overview, geographic revenue break up, segment wise revenue break up, along with key financials, have been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of the players. At the end, a section has been dedicated to the future outlook. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the biosimilars industry.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Biologics Market Outlook to 2020
3.1 Market Size
3.2 Market Segmentation
4. Global Biosimilars Market Outlook 2020
4.1 Market Size
4.2 Market Segmentation by Application
4.2.1 Erythropoietin (EPO)
4.2.2 Human Growth Hormone (HGH)
4.2.3 Granulocyte- Colony Stimulating Factor (G-CSF)
4.2.4 Monoclonal Antibody (mAb)
4.2.5 Insulin
4.2.6 Interferon (IFN)
4.3 Market Segmentation by Geography
4.3.1 Europe
4.3.2 Asia-Pacific
4.3.3 Others
5. Market Drivers and Challenges
5.1 Drivers
5.1.1 Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market
5.1.2 Shrinking Healthcare Budgets to Carve Way for Biosimilars
5.1.3 Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
5.2 Challenges
5.2.1 Need for the Development of Manufacturing Capabilities
5.2.2 Greater Litgation Risk
5.2.3 High Cost of Development Accompanied with Low Adoption
5.2.4 Interchangeability/ Substitutability
6. Market Trends and Developments
6.1 Plant based Manufacturing Platforms for Biosimilars
6.2 Developing Economies Emerge as Potential Markets for Biosimilar Production
7. Mergers and Acquisitions
8. Porters Five Forces Model
9. Competitive Landscape
9.1 Market Share of Major Players
9.2 Profiles
9.2.1 Biocad
9.2.2 Celltrion
9.2.3 Dong-A Pharmaceutical Co., Ltd
9.2.4 Hospira
9.2.5 Intas
9.2.6 Sandoz
9.2.7 Stada Arzneimittel
9.2.8 Teva
10. Future Outlook

List of Figures:

Figure 3-1: Global – Biologics Market (Billion US$), 2014-2020
Figure 3-2: Share of Biologics in Sales of Top 100 Pharma Products
Figure 3-3: Global – Biologics Market by Segment (%), 2014
Figure 4-1: Global – Biosimilars Market (Billion US$), 2014-2020
Figure 4-2: Global – Biosimilars Market by Key Segment (%), 2014
Figure 4- 3: Global – Biosimilars Market by Key Segment (%), 2020
Figure 4-4: Global – Erythropoietin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-5: Global – HGH Biosimilars Market (Million US$), 2014 & 2020
Figure 4-6: Global – G-CSF Biosimilars Market (Million US$), 2014 & 2020
Figure 4-7: Global – mAb Biosimilars Market (Million US$), 2014 & 2020
Figure 4-8: Global – Insulin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-9: Global – Interferon Biosimilars Market (Million US$), 2014 & 2020
Figure 4-10: Europe – Biosimilars Market (Million US$), 2014-2020
Figure 4-11: Europe – Biosimilars Market by Country (%), 2014
Figure 4-12: Asia – Pacific – Biosimilars Market (Billion US$), 2014-2020
Figure 4-13: Asia – Pacific – Biosimilars Market by Country (%), 2014
Figure 4-14: Others – Biosimilars Market (Billion US$), 2014-2020
Figure 5-1: World’s Best Selling Biologics and their Patent Expiry in the US
Figure 9-1: Market Share of Major Players in the Biosimilar Industry, 2014
Figure 9-2: Hospira – Breakdown of Revenue by Geographic Segment (%), 2013
Figure 9-3: Hospira – Breakdown of Revenue by Industry Segment (%), 2013
Figure 9-4: Sandoz – Global Sales (Billion USD), 2011-2013
Figure 9-5: Sandoz – Breakdown of Revenue by Geographic Segment (Billion USD), 2011-2013

List of Tables:

Table 4-1: Global – Patent Expiry Status of EPOs
Table 4-2: Global – Biosimilar EPOs Approved for Marketing
Table 4-3: Global – Biosimilar EPOs in Pipeline
Table 4-4: Global – Biosimilar HGH Approved for Marketing
Table 4-5: Global – Biosimilar HGH in Pipeline
Table 4-6: Global – Biosimilar G-CSF Approved for Marketing
Table 4-7: Global Biosimilar G-CSF Market – Key Players by Rank
Table 4-8: Global – Biosimilar G-CSF in Pipeline
Table 4-9: Global – Patent Expiry Status of G-CSF
Table 4-10: Global – Biosimilar mAbs Approved for Marketing
Table 4-11: Global Biosimilar mAb Market – Key Players by Rank
Table 4-12: Global – Biosimilar mAbs in Pipeline
Table 4-13: Global – Patent Expiry Status of mAbs
Table 4-14: Global – Biosimilar Insulin Approved for Marketing
Table 4-15: Global Biosimilar Insulin Market – Key Players by Rank
Table 4-16: Global – Biosimilar Insulin in Pipeline
Table 4-17: Global – Patent Expiry Status of Insulin
Table 4-18: Global – Biosimilar Interferons Approved for Marketing
Table 4-19: Global – Biosimilar Interferons in Pipeline
Table 4-20: Global – Patent Expiry Status of Interferons
Table 7-1: Global – Major M&A Activity in the Past Year
Table 9-1: Biocad – Biosimilars Approved for Marketing
Table 9-2: Biocad – Biosimilars in Pipeline
Table 9-3: Biocad – Strengths & Weaknesses
Table 9-4: Celltrion – Key Financials (Million KRW), 2011-2013
Table 9-5: Celltrion – Biosimilars Approved for Marketing
Table 9-6: Celltrion – Biosimilars in Pipeline
Table 9-7: Celltrion – Strengths & Weaknesses
Table 9-8: Dong-A Pharmaceutical – Key Financials (Billion Won), 2011-2013
Table 9-9: Dong-A Pharmaceutical – Biosimilars in Pipeline
Table 9-10: Dong-A Pharmaceutical – Strengths & Weaknesses
Table 9-11: Hospira – Key Financials (Million Dollars), 2011-2013
Table 9-12: Hospira – Biosimilars Approved for Marketing
Table 9-13: Hospira – Biosimilars in Pipeline
Table 9-14: Hospira – Strengths & Weaknesses
Table 9-15: Intas – Biosimilars Approved for Marketing
Table 9-16: Intas – Biosimilars in Pipeline
Table 9-17: Intas – Strengths & Weaknesses
Table 9-18: Sandoz – Biosimilars Approved for Marketing
Table 9-19: Sandoz – Biosimilars in Pipeline
Table 9-20: Sandoz – Strengths & Weaknesses
Table 9-21: Stada – Biosimilars Approved for Marketing
Table 9-22: Stada – Biosimilars in Pipeline
Table 9-23: Stada – Strengths & Weaknesses
Table 9-24: Teva – Biosimilars Approved for Marketing
Table 9-25: Teva – Strengths & Weaknesses



【レポートのキーワード】

バイオシミラー(バイオ後続品)、エリトロポエチン、ヒト成長ホルモン、果粒球コロニー刺激因子、モノクローナル抗体、インシュリン、インターフェロン、医薬品

★調査レポート[世界のバイオシミラー(バイオ後続品)市場動向:エリトロポエチン、ヒト成長ホルモン、果粒球コロニー刺激因子、モノクローナル抗体など] (コード:RNCOS5042101)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のバイオシミラー(バイオ後続品)市場動向:エリトロポエチン、ヒト成長ホルモン、果粒球コロニー刺激因子、モノクローナル抗体など]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆